
    
      A Phase II randomised, multicenter study to assess the efficacy and safety of continuing
      erlotinib in addition to chemotherapy versus chemotherapy alone in patients who have EGFR
      mutant or EGFR TKI responsive NSCLC and have progressed on EGFR TKI.
    
  